A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Colorectal Cancer · Pancreatic Ductal Adenocarcinoma · Biliary Tract Cancer

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • UCLA ( Site 0317), Los Angeles, California, United States

    Study coordinator · 310-633-8400
  • University of Colorado Anschutz Medical Campus ( Site 0299), Aurora, Colorado, United States

    Study coordinator · 303-724-8644
  • University of Colorado Anschutz Medical Campus ( Site 0325), Aurora, Colorado, United States

    Study coordinator · 720-848-0300
  • University of Colorado Anschutz Medical Campus ( Site 0326), Aurora, Colorado, United States

    Study coordinator · 720-848-0300
  • Sibley Memorial Hospital ( Site 0310), Washington D.C., District of Columbia, United States

    Study coordinator · 202-660-6500
  • University of Florida College of Medicine ( Site 0281), Gainesville, Florida, United States

    Study coordinator · 352-265-5121
  • Mount Sinai Cancer Center ( Site 0287), Miami Beach, Florida, United States

    Study coordinator · 305-674-2625
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0303), Marietta, Georgia, United States

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327), Mineola, New York, United States

    Study coordinator · 646-599-4083
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324), New York, New York, United States

    Study coordinator · 212-731-6000
  • University of Texas MD Anderson Cancer Center ( Site 0316), Houston, Texas, United States

    Study coordinator · 713-792-2828
  • Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 0295), Roanoke, Virginia, United States

    Study coordinator · 540-491-2240
  • University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293), Madison, Wisconsin, United States

    Study coordinator · 800-622-8922
  • Westmead Hospital ( Site 0003), Westmead, New South Wales, Australia

    Study coordinator · +61288908935
  • Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 0001), Brisbane, Queensland, Australia

    Study coordinator · +61736467712
  • Epworth Freemasons ( Site 0005), East Melbourne, Victoria, Australia

    Study coordinator · +61394268996
  • Frankston Hospital-Oncology and Haematology ( Site 0004), Frankston, Victoria, Australia

    Study coordinator · +61397848152
  • One Clinical Research ( Site 0002), Nedlands, Western Australia, Australia

    Study coordinator · +61862799466
  • The Ottawa Hospital Cancer Centre ( Site 0027), Ottawa, Ontario, Canada

    Study coordinator · 613-737-7700 x70185
  • Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0022), Montreal, Quebec, Canada

    Study coordinator · 5148908000
  • McGill University Health Centre ( Site 0023), Montreal, Quebec, Canada

    Study coordinator · 514 934-1934
  • James Lind Centro de Investigacion del Cancer ( Site 0048), Temuco, Araucania, Chile

    Study coordinator · +56452982404
  • FALP-UIDO ( Site 0041), Providencia, Region M. de Santiago, Chile

    Study coordinator · +56228205798
  • Clínica UC San Carlos de Apoquindo ( Site 0043), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56227548924
  • Bradfordhill-Clinical Area ( Site 0047), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56991291852
  • Beijing Cancer hospital-Digestive Oncology ( Site 0061), Beijing, Beijing Municipality, China

    Study coordinator · 010-88196340
  • The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 0063), Fuzhou, Fujian, China

    Study coordinator · 0591-22859663
  • Wuhan Union Hospital Cancer Center. ( Site 0064), Wuhan, Hubei, China

    Study coordinator · 027-83262682
  • Hunan Cancer Hospital-intervention department ( Site 0066), Changsha, Hunan, China

    Study coordinator · 0731-89762041
  • Renji Hospital Shanghai Jiao Tong University School of Medicine-Oncology Department ( Site 0067), Shanghai, Shanghai Municipality, China

    Study coordinator · 021-68383223
  • West China Hospital, Sichuan University ( Site 0068), Chengdu, Sichuan, China

    Study coordinator · 028-85423203
  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0101), Milan, Lombardy, Italy

    Study coordinator · 390223903807
  • ASST Grande Ospedale Metropolitano Niguarda ( Site 0102), Milan, Lombardy, Italy

    Study coordinator · 390264442291
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 0103), Roma, Italy

    Study coordinator · 390458128116
  • National Cancer Center Hospital East ( Site 0121), Kashiwa, Chiba, Japan

    Study coordinator · +81-4-7133-1111
  • Kanagawa Cancer Center ( Site 0122), Yokohama, Kanagawa, Japan

    Study coordinator · +81-45-520-2222
  • Seoul National University Hospital ( Site 0161), Seoul, South Korea

    Study coordinator · 82-2-2072-0701
  • Severance Hospital, Yonsei University Health System ( Site 0164), Seoul, South Korea

    Study coordinator · 82-2-2228-8137
  • Asan Medical Center ( Site 0163), Seoul, South Korea

    Study coordinator · +82 2 3010 3945
  • Samsung Medical Center ( Site 0162), Seoul, South Korea

    Study coordinator · +82234103549
  • HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 0183), Madrid, Madrid, Comunidad de, Spain

    Study coordinator · 914269070
  • Hospital Universitario Central de Asturias-Medical Oncology ( Site 0182), Oviedo, Principality of Asturias, Spain

    Study coordinator · 34 985108000x36582
  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0181), Barcelona, Spain

    Study coordinator · +34 93 274 60 60
  • Hôpitaux Universitaires de Genève (HUG) ( Site 0202), Geneva, Canton of Geneva, Switzerland

    Study coordinator · +41223729862
  • Ospedale Regionale Bellinzona e Valli ( Site 0201), Bellinzona, Canton Ticino, Switzerland

    Study coordinator · +41918119039
  • China Medical University Hospital ( Site 0223), Taichung, Taiwan

    Study coordinator · +886422052121
  • National Cheng Kung University Hospital-Clinical Trial Center ( Site 0224), Tainan, Taiwan

    Study coordinator · 88662353535
  • National Taiwan University Hospital-Oncology ( Site 0225), Taipei, Taiwan

    Study coordinator · +886223123456
  • Taipei Veterans General Hospital ( Site 0221), Taipei, Taiwan

    Study coordinator · +886228712121
  • Chang Gung Medical Foundation-Linkou Branch ( Site 0222), Taoyuan, Taiwan

    Study coordinator · +88633281200x8825
  • Hacettepe Universite Hastaneleri-oncology hospital ( Site 0241), Ankara, Turkey (Türkiye)

  • Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 0242), Ankara, Turkey (Türkiye)

  • Barts Health NHS Trust ( Site 0263), London, England, United Kingdom

    Study coordinator · 07918804584
  • Royal Free Hospital ( Site 0262), London, England, United Kingdom

    Study coordinator · 02077940500 ext38682
  • University Hospital Coventry & Warwickshire ( Site 0266), Coventry, United Kingdom

    Study coordinator · 02476967485
מובילי המחקר
  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC